Skip to main content
SpringerLink
Log in

Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis

  • Research Letter
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Reynolds KA, Pithadia DJ, Lee EB, et al. Safety and effectiveness of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis. Am J Clin Dermatol. 2020. https://doi.org/10.1007/s40257-020-00507-1.

    Article  PubMed  Google Scholar 

  2. Gisondi P, Virga C, Piaserico S, et al. Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19013.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lauret A, Moltó A, Abitbol V, et al. Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Semin Arthritis Rheum. 2020. https://doi.org/10.1016/J.SEMARTHRIT.2020.02.007.

    Article  PubMed  Google Scholar 

  4. Kiltz U, Tsiami S, Baraliakos X, et al. Effects of successive switches of two different biosimilars of etanercept on outcomes in inflammatory rheumatic diseases in daily practice. Ann Rheum Dis. 2020;79:1876LP.

    Google Scholar 

  5. Atiqi S, Hooijberg F, Loeff FC, et al. Immunogenicity of TNF-inhibitors. Front Immunol. 2020;11:312. https://doi.org/10.3389/fimmu.2020.00312.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gerdes S, Thaçi D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018;32(3):420–7. https://doi.org/10.1111/jdv.14605.

    Article  CAS  PubMed  Google Scholar 

  7. Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–19. https://doi.org/10.1111/bjd.16102.

    Article  CAS  PubMed  Google Scholar 

  8. Planès S, Villier C, Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect. 2016;4(2):e00208. https://doi.org/10.1002/prp2.208.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Dermatology and Venereology, Unit of Dermatology, Department of Medicine, University of Padua, Via V. Gallucci 4, 35128, Padua, Italy

    Stefano Piaserico, Francesco Messina & Alberto Meneguzzo

  2. Dermatologic Unit, Department of Specialized Medicine, AOU Policlinico di Modena, Modena, Italy

    Andrea Conti & Giulia Odorici

  3. Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy

    Francesco Bellinato & Paolo Gisondi

Authors
  1. Stefano Piaserico
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Messina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alberto Meneguzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giulia Odorici
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francesco Bellinato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paolo Gisondi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano Piaserico.

Ethics declarations

Funding

No funding was needed for this study.

Conflict of interest

Stefano Piaserico has been a consultant and/or speaker for Abbvie, Almirall, Celgene, Janssen, Leo-pharma, Eli Lilly, Novartis, Sandoz, UCB; Andrea Conti has been a consultant and/or speaker for Abbvie, Janssen, Eli Lilly, Novartis, Pfizer and UCB; Francesco Messina has no conflict of interest; Alberto Meneguzzo has no conflict of interest; Giulia Odorici has no conflict of interest; Francesco Bellinato has no conflict of interest; Paolo Gisondi has been a consultant and/or speaker for Abbvie, Almirall, Celgene, Janssen, Leo-pharma, Eli Lilly, Novartis, Pfizer, Sandoz, UCB.

Authors’ contributions

SP, AC and PG designed the study, wrote the article and revised it critically; FM, AM, GO and FB collected the data and participated in the writing of the article and its revision.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Code availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piaserico, S., Conti, A., Messina, F. et al. Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis. BioDrugs 35, 469–471 (2021). https://doi.org/10.1007/s40259-021-00485-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-021-00485-8

Search

Navigation